Physician profile
Sameera Tallapureddy
NPI 1669642799
$140,055.41
in general payments reported to CMS, 2019-2025
63 companies · $51K in 2025
The $51K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,751 · 2020: $2,363 · 2021: $2,156 · 2022: $1,918 · 2023: $47K · 2024: $33K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Travel and Lodging: $14K · Food and Beverage: $11K · Consulting Fee: $10K · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,225.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,704.00 |
| Travel and Lodging | $13,904.22 |
| Food and Beverage | $10,551.99 |
| Consulting Fee | $10,375.00 |
| Education | $106.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $82,903.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $28,789.07 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Eli Lilly and Company | $11,453.60 | 2023-2024 | |
| Ascensia Diabetes Care US INC. | $2,991.75 | 2021-2025 | |
| Mannkind Corporation | $1,320.53 | 2019-2025 | Afrezza |
| Novo Nordisk INC | $1,264.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,113.16 | 2019-2022 | |
| Amgen INC. | $1,099.57 | 2019-2025 | Evenity, Tepezza, Prolia |
| Corcept Therapeutics | $816.44 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $575.24 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $511.12 | 2019-2025 | |
| Abbott Laboratories | $472.01 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.13 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $428.10 | 2022-2025 | |
| Abbvie INC. | $411.70 | 2019-2025 | Ubrelvy |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $351.30 | 2021-2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Merck Sharp & Dohme LLC | $267.93 | 2019-2022 | |
| Radius Health, INC. | $267.75 | 2019-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $263.44 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Vivus LLC | $261.84 | 2019-2024 | Qsymia |
| Ibsa Pharma INC. | $256.10 | 2019-2025 | Tirosint, Tirosint, Licart |
| Amarin Pharma, INC. | $255.05 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $227.54 | 2020-2025 | Unithroid |
| Antares Pharma, INC. | $223.56 | 2019-2022 | |
| Insulet Corporation | $217.81 | 2019-2024 | Omnipod |
| Horizon Therapeutics Plc | $217.38 | 2021-2023 | Tepezza |
| Valeritas, INC. | $213.97 | 2019 | |
| Recordati_rare_diseases_inc. | $199.22 | 2022-2025 | Isturisa, Signifor Lar |
| Sequel Med Tech, LLC | $174.17 | 2025 | Twiist |
| Medtronic Minimed, INC. | $170.45 | 2019-2020 | |
| Clarus Therapeutics INC. | $165.45 | 2021 | |
| Astellas Pharma US INC | $162.08 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $155.97 | 2020-2021 | |
| Aytu Biopharma, INC. | $147.64 | 2019-2020 | |
| Zealand Pharma US, INC. | $129.51 | 2020-2022 | |
| Nevro Corp. | $87.09 | 2021 | |
| Eusa Pharma (US) LLC | $73.04 | 2022 | |
| Companion Medical, INC. | $71.86 | 2019-2020 | |
| Avvisto Therapeutics, LLC | $67.72 | 2024-2025 | Cycloset |
| Shire North American Group INC | $63.93 | 2019 | |
| Currax Pharmaceuticals LLC | $63.14 | 2019-2024 | Contrave |
| Beta Bionics, INC. | $56.18 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.82 | 2019 | |
| Pfizer INC. | $45.87 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $45.87 | 2020 | |
| Acerus Pharmaceuticals Corporation | $43.18 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $41.37 | 2025 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $37.83 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.03 | 2021 | |
| Boston Scientific Corporation | $35.34 | 2025 | Wavewriter Alpha Prime 16 |
| Opko Pharmaceuticals, LLC | $30.70 | 2019 | |
| Soleno Therapeutics, INC. | $29.85 | 2025 | Vykat Xr |
| Verity Pharmaceuticals INC. | $28.96 | 2025 | Tlando |
| Cequr Corporation | $28.88 | 2022 | |
| Kyowa Kirin, INC. | $26.90 | 2024 | Crysvita |
| Neurocrine Biosciences, INC. | $24.25 | 2024 | |
| Madrigal Pharmaceuticals | $23.34 | 2025 | Rezdiffra |
| Ascendis Pharma Endocrinology INC | $18.61 | 2025 | Yorvipath |
| Globus Medical, INC. | $17.19 | 2025 | Senza |
| Alvogen INC | $16.19 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.12 | 2025 | Givlaari |
| Amryt Pharma Holdings LTD | $16.02 | 2023 | Mycapssa |
| Acella Pharmaceuticals, LLC | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameera Tallapureddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.